ETF Managers Group LLC boosted its holdings in Boston Scientific Co. (NYSE:BSX) by 17.3% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 4,835 shares of the medical equipment provider’s stock after purchasing an additional 712 shares during the quarter. ETF Managers Group LLC’s holdings in Boston Scientific were worth $171,000 at the end of the most recent quarter.
A number of other institutional investors have also added to or reduced their stakes in BSX. We Are One Seven LLC acquired a new position in Boston Scientific in the fourth quarter worth $27,000. Ipswich Investment Management Co. Inc. acquired a new position in Boston Scientific in the fourth quarter worth $28,000. CWM LLC boosted its holdings in Boston Scientific by 54.3% in the fourth quarter. CWM LLC now owns 1,020 shares of the medical equipment provider’s stock worth $36,000 after purchasing an additional 359 shares during the period. West Oak Capital LLC boosted its holdings in Boston Scientific by 40.0% in the fourth quarter. West Oak Capital LLC now owns 1,050 shares of the medical equipment provider’s stock worth $37,000 after purchasing an additional 300 shares during the period. Finally, Exane Derivatives boosted its holdings in Boston Scientific by 116,300.0% in the fourth quarter. Exane Derivatives now owns 1,164 shares of the medical equipment provider’s stock worth $41,000 after purchasing an additional 1,163 shares during the period. 91.60% of the stock is owned by hedge funds and other institutional investors.
In related news, SVP Maulik Nanavaty sold 3,038 shares of Boston Scientific stock in a transaction dated Tuesday, January 15th. The shares were sold at an average price of $35.46, for a total transaction of $107,727.48. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, SVP Eric Francis Yves Thepaut sold 15,298 shares of Boston Scientific stock in a transaction dated Thursday, November 29th. The shares were sold at an average price of $36.74, for a total transaction of $562,048.52. Following the sale, the senior vice president now owns 98,884 shares in the company, valued at $3,632,998.16. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 91,724 shares of company stock worth $3,350,373. Company insiders own 0.73% of the company’s stock.
Shares of NYSE BSX opened at $39.19 on Monday. Boston Scientific Co. has a fifty-two week low of $25.04 and a fifty-two week high of $39.44. The company has a current ratio of 0.78, a quick ratio of 0.56 and a debt-to-equity ratio of 0.58. The stock has a market cap of $54.23 billion, a P/E ratio of 26.48, a P/E/G ratio of 2.30 and a beta of 0.83.
Boston Scientific (NYSE:BSX) last issued its quarterly earnings data on Wednesday, February 6th. The medical equipment provider reported $0.39 earnings per share for the quarter, beating analysts’ consensus estimates of $0.37 by $0.02. Boston Scientific had a net margin of 17.01% and a return on equity of 26.80%. The business had revenue of $2.56 billion for the quarter, compared to analysts’ expectations of $2.57 billion. During the same period in the previous year, the business earned $0.34 earnings per share. The company’s revenue was up 6.4% on a year-over-year basis. As a group, analysts predict that Boston Scientific Co. will post 1.56 earnings per share for the current fiscal year.
A number of research firms have issued reports on BSX. Needham & Company LLC reiterated a “buy” rating and issued a $43.00 target price on shares of Boston Scientific in a research note on Wednesday, February 6th. Guggenheim reiterated a “buy” rating and issued a $48.00 target price on shares of Boston Scientific in a research note on Friday. Oppenheimer set a $38.00 target price on Boston Scientific and gave the company a “hold” rating in a research note on Wednesday, October 24th. Zacks Investment Research cut Boston Scientific from a “hold” rating to a “sell” rating in a research note on Monday, December 31st. Finally, SunTrust Banks reiterated a “buy” rating and issued a $47.00 target price on shares of Boston Scientific in a research note on Friday. Three investment analysts have rated the stock with a hold rating, twenty-two have assigned a buy rating and two have issued a strong buy rating to the stock. Boston Scientific presently has a consensus rating of “Buy” and a consensus target price of $40.35.
Boston Scientific Profile
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: Cardiovascular, Rhythm Management, and MedSurg. The company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions therapy products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as certain peripheral vessels; and structural heart therapy systems.
Featured Story: How dollar cost averaging works
Want to see what other hedge funds are holding BSX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Boston Scientific Co. (NYSE:BSX).